Next Article in Journal
ΔNp73, TAp73 and Δ133p53 Extracellular Vesicle Cargo as Early Diagnosis Markers in Colorectal Cancer
Previous Article in Journal
Reply to Krupenko et al. Comment on “Lee et al. The Combination of Loss of ALDH1L1 Function and Phenformin Treatment Decreases Tumor Growth in KRAS-Driven Lung Cancer Cancers 2020, 12, 1382”
Article

Metronomic Chemotherapy Modulates Clonal Interactions to Prevent Drug Resistance in Non-Small Cell Lung Cancer

1
Centre de Recherche en Cancérologie de Marseille, Aix-Marseille Université, Inserm, CNRS, Institut Paoli Calmettes, 13273 Marseille, France
2
Assistance Publique-Hopitaux de Marseille (AP-HM), Timone Hospital, 13385 Marseille, France
3
Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3525433, Israel
4
Metronomics Global Health Initiative, 13385 Marseille, France
5
Centrale Marseille, CNRS, Aix Marseille Université, 13013 Marseille, France
6
Institut Denis Poisson, Université d’Orléans, CNRS, 45100 Orléans, France
7
Service d’Hématologie & Oncologie Pédiatrique, AP-HM, 13385 Marseille, France
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: David J. Waxman
Cancers 2021, 13(9), 2239; https://doi.org/10.3390/cancers13092239
Received: 30 March 2021 / Revised: 28 April 2021 / Accepted: 5 May 2021 / Published: 7 May 2021
Inside a tumor mass, drug resistant and sensitive cell populations co-exist, leading to a therapeutic challenge in oncology. In this study, we developed 2D and 3D co-culture systems and mathematical modeling to better understand how these different populations impact each other. We demonstrated that drug-sensitive cell populations inhibit the growth of drug-resistant populations. Mathematical modeling predicted that metronomic schedules, using chronic administration of drugs at low doses, could better control intratumor cell dynamics. We validated our in silico data in 3D and in vivo models. Finally, we demonstrated that metabolic cell activity of drug-sensitive cells could play a key role in controlling the proliferation of drug-resistant cells. Altogether, our study reports a new mechanism of action of metronomic therapy and paves the way for using it to better control drug resistance.
Despite recent advances in deciphering cancer drug resistance mechanisms, relapse is a widely observed phenomenon in advanced cancers, mainly due to intratumor clonal heterogeneity. How tumor clones progress and impact each other remains elusive. In this study, we developed 2D and 3D non-small cell lung cancer co-culture systems and defined a phenomenological mathematical model to better understand clone dynamics. Our results demonstrated that the drug-sensitive clones inhibit the proliferation of the drug-resistant ones under untreated conditions. Model predictions and their experimental in vitro and in vivo validations indicated that a metronomic schedule leads to a better regulation of tumor cell heterogeneity over time than a maximum-tolerated dose schedule, while achieving control of tumor progression. We finally showed that drug-sensitive and -resistant clones exhibited different metabolic statuses that could be involved in controlling the intratumor heterogeneity dynamics. Our data suggested that the glycolytic activity of drug-sensitive clones could play a major role in inhibiting the drug-resistant clone proliferation. Altogether, these computational and experimental approaches provide foundations for using metronomic therapy to control drug-sensitive and -resistant clone balance and highlight the potential of targeting cell metabolism to manage intratumor heterogeneity. View Full-Text
Keywords: metronomic chemotherapy; intratumor heterogeneity; mathematical modeling; non-small cell lung cancer; glycolytic activity; lactate dehydrogenase metronomic chemotherapy; intratumor heterogeneity; mathematical modeling; non-small cell lung cancer; glycolytic activity; lactate dehydrogenase
Show Figures

Figure 1

MDPI and ACS Style

Bondarenko, M.; Le Grand, M.; Shaked, Y.; Raviv, Z.; Chapuisat, G.; Carrère, C.; Montero, M.-P.; Rossi, M.; Pasquier, E.; Carré, M.; André, N. Metronomic Chemotherapy Modulates Clonal Interactions to Prevent Drug Resistance in Non-Small Cell Lung Cancer. Cancers 2021, 13, 2239. https://doi.org/10.3390/cancers13092239

AMA Style

Bondarenko M, Le Grand M, Shaked Y, Raviv Z, Chapuisat G, Carrère C, Montero M-P, Rossi M, Pasquier E, Carré M, André N. Metronomic Chemotherapy Modulates Clonal Interactions to Prevent Drug Resistance in Non-Small Cell Lung Cancer. Cancers. 2021; 13(9):2239. https://doi.org/10.3390/cancers13092239

Chicago/Turabian Style

Bondarenko, Maryna, Marion Le Grand, Yuval Shaked, Ziv Raviv, Guillemette Chapuisat, Cécile Carrère, Marie-Pierre Montero, Mailys Rossi, Eddy Pasquier, Manon Carré, and Nicolas André. 2021. "Metronomic Chemotherapy Modulates Clonal Interactions to Prevent Drug Resistance in Non-Small Cell Lung Cancer" Cancers 13, no. 9: 2239. https://doi.org/10.3390/cancers13092239

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop